What is KRAZATI used for?

1 INDICATIONS AND USAGE KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or m

How does KRAZATI work?

11 DESCRIPTION Adagrasib is an irreversible inhibitor of KRAS G12C and belongs to the RAS GTPase family.

What pharmaceutical form is KRAZATI available in?

KRAZATI: Tabletki powlekane 200 mg (doustna)

Is KRAZATI OTC or prescription only?

KRAZATI requires a doctor's prescription.

What are the side effects of KRAZATI?

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.1) ] • QTc Interval Prolongation [see Warnings and Precautions (5.2) ] • Hepatotoxicity [see Warnings and Precautions (5.3) ] • Interstitial Lung Disease (ILD)/Pneumonitis [see Warnings and Precautions (5.4) ] • Single agent use in NCSLC: The most common adverse reactions (≥ 25%) were nausea, diarrhea, vomiting,

Who should NOT take KRAZATI?

4 CONTRAINDICATIONS None. None. ( 4 )

Does KRAZATI interact with other medications?

7 DRUG INTERACTIONS See full prescribing information for clinically significant drug interactions with KRAZATI. ( 7 ) • Strong CYP3A4 Inducers : Avoid concomitant use. ( 7.1 ) • Strong CYP3A4 Inhibitors : Avoid concomitant use until adagrasib concentrations have reached steady state. ( 7.1 ) • Sensitive CYP3A4 Substrates : Avoid concomitant use with sensitive CYP3A4 substrates. ( 7.2 ) • Sensitive CYP2C9 or CYP2D6 Substrates or P-gp Substrates : Avoid concomitant use with sensi

Can KRAZATI be used during pregnancy?

8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary There are no available data on the use of KRAZATI in pregnant women. In animal reproduction studies, oral administration of adagrasib to pregnant rats and rabbits during the period of organogenesis did not cause adverse development effects or embryo-fetal lethality at exposures below the human exposure at the recommended dose of 600 mg twice daily (see Data) . In the U.S. gene

Who manufactures KRAZATI?

Bristol-Myers Squibb Pharma EEIG (Irlandia)

What ATC class does KRAZATI belong to?

KRAZATI: ATC L01XX77. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

KRAZATI

200 mg, Tabletki powlekane

INN: Adagrasibum

Data updated: 2026-04-13

Available in:

🇨🇿🇩🇪🇬🇧🇫🇷🇵🇱🇵🇹🇸🇰🇺🇦

Form

Tabletki powlekane

Dosage

200 mg

Route

doustna

Storage

Storage and Handling Store tablets at room temperature, 20°C to 25°C (68°F to 77°F).‍‍‍‍‍‍‍‍ Temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted [see USP Controlled Room Temperature] .

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.